Evaluation of the effacay of the intravesical thermochemotherapy with mitomycin C in intermediate risk superficial bladder tumors recurrent after BCG. - ND

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO0 个研究点开始时间: 2008年9月26日最近更新: 2012年3月19日

试验速览

暂无简介。

•patients with transitional cell carcinoma of the bladder, Ta or T1, G1-2, mono- or multifocal (except multifocal T1G2), recurred after at least one complete induction cycle of BCG
•informed consensus
•WHO performance status 0-2 , age less than 85
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•high risk superficial bladder tumor (T1G3, CIS, T1G2 multifocal, positive urinary citology ) or invasive bladder tumor
•not transitional cell bladder tumor
•WHO performance status 3-4, age more than 85
•troubles in carrying out a follow-up because of distance or other illnesses
•WBC less than 3000/mm3 and/or PLT less than 100000/mm3
•altered renal and hepatic function
•urinary infections
•insufficient bladder capacity
•no BCG treatment
•transitional cell carcinoma within prostatic urethra or ureters/renal pelvis
•pregnancy or breastfeeding
•metastatic desease (except for basalioma)

发起方

AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO